Ji-Hong HONG MD, PhD

Proton therapy

Gynecologic tumors, Prostate cancer, Genitourinary tumors, Gastrointestinal tumors


Ji-Hong Hong is a radiation oncologist with high reputation in Taiwan.  He had been the chairman of the Department of Radiation Oncology (RTO), Chang Gung Memorial Hospital (CGMH) at Linkou since 1997 and was promoted to vice superintendent after 2014.   Under his leadership, RTO of CGMH-Linkou is the largest and best one in Taiwan.  He set up the proton therapy center at CGMH, the first one in Taiwan, which started treating service in Nov. 2015.  He is the most experienced physician in proton treatment in Taiwan.

Dr. Hong obtained his MD degree from Taipei Medical University, Taiwan and Ph.D. in Biomedical Physics Program from UCLA, USA.  Dr. Hong’s clinical sub-specialties were in gynecological, genitourinary and gastrointestinal cancers.  He publishes around 150 papers in leading oncology journals and gained international reputation; these papers have strong clinical impact and are being cited in the textbooks of radiation oncology.  Dr. Hong is also a physician scientist major in biological studies and published many papers in high-ranking scientific journals.

Dr. Hong was selected as one of the best 100 physicians and among the best 10 oncologist list in Taiwan by “Business Weekly” periodical, which conducted this survey by surveying the opinions from medical experts, medical associations and patients. He was the President of the Taiwan Society for Therapeutic Radiology and Oncology in year 2014-2016.


Proton therapy. Radiotherapy for gynecological, genitourinary, liver and pancreatic cancers.

Treatment Cases

Treated >1500 Gynecological cancer patients,  >1000 Genitourinary (mainly prostate and bladder) cancer patients and >250 liver tumors。For cancers mainly treated by radiotherapy, such as advanced cervical cancer or prostate cancer, our patients’ 5-year survival rate is significantly better than the average of medical center in Taiwan.

For hepatocellular carcinoma not suitable for surgery or RFA, our one-year survival rate for patients can fit our proton treatment protocol is around 90%.  This figure is same as the proton therapy outcome reported from Japan and much better than those treated by target therapy or TACE.

Medical Contributions

Set up the first proton therapy center in Taiwan.

The first one in Taiwan to introduce new technologies such as High-dose-rate brachytherapy for prostate cancer, intensity-modulated radiotherapy (IMRT), RapidArc, Novalis.

The clinical research in cervical cancer have changed the international practice guideline.


1977 - 1984, MD, Taipei Medical University

1990 - 1995, PhD, Biomedical Physics Program, UCLA


1984 - 1988, Resident, Department of Radiation Oncology (RTO), CGMH。

1988 - 1990, Attending physician, RTO, CGMH

1990 - 1995, Research Assistant in RTO, Experimental Division, UCLA

1995, Post-doctor in RTO, Experimental Division, UCLA

1995 - 1997, Attending physician, RTO, CGMH

1995 - 2005, Associate Professor, Chang Gung University

1997 - 1998, Director of Radiological Division, Department of Medical Technology, School of Medicine, Chang Gung University

1997 - 2014, Director, RTO, CGMH

2000 - 2004, Director, Cancer Center, CGMH at Linkou

2004 - 2010, Deputy Director of Cancer Center,

2010 - 2012, Director, Cancer Center, CGMH

2012 - 2017, Chairman, Cancer committee, Chang Gung System.

2014 - 2017, Vice superintendent, CGMH at Linkou

Current Appointment

Vice superintendent supervising Department of Radiation Oncology and Proton Center

Attending Physician, Department of Radiation Oncology, Chang Gung Memorial Hospital at Linkou

Professor, Chang Gung University

Professor Physician, CGMH


The best 100 physicians and among the best 10 oncologist list in Taiwan by “Business Weekly” periodical.

Publications after 2012 (*Corresponding authors)

  1. P. Y. Hsu, S. H. Yang, N. M. Tsang, K. M. Fan, C. H. Hsieh, J. R. Lin, J. H. Hong, Y. C. Lin, H. Y. Chen, C. T. Yang, C. W. Yang, J. L. Chen. Efficacy of Traditional Chinese Medicine in Xerostomia and Quality of Life during Radiotherapy for Head and Neck Cancer: A Prospective Pilot Study. Evid Based Complement Alternat Med. 2016;2016:8359251. doi: 10.1155/2016/8359251. Epub 2016 Aug 21. (SCI)
  2. Y. S. Lin, T. C. Chao, J. H. Hong, and C. J. Tung   Comparisons of longitudinal and lateral dose profiles and relative biological effectiveness for DNA double strand breaks among 1H, 4He and 12C beams.  2017; Radiat. Physics Chem. In press. (SCI)
  3. S. K. Chen, B. H. Chiang, C. C. Lee, C. J. Tung, J. H. Hong and T. C. Chao  The impact of MCS models and EFAC values on the dose simulation for a proton pencil beam.  Radiat. Physics Chem. 137: 29-32. 2017 Aug. (SCI)
  4. Y. C. Lin YC, G. Lin G, J. H. Hong, Y. P. Lin, F. H. Chen, S. H. Ng, C. C. Wang Diffusion radiomics analysis of intratumoral heterogeneity in a murine prostate cancer model following radiotherapy: Pixelwise correlation with histology. J Magn Reson Imaging.  46:483-489, 2017 Aug.  (SCI)
  5. T. C. Chao, Y. C. Tsai, S. K. Chen, S. W. Wu, C. J. Tung, J. H. Hong, C. C. Wang and C. C. Lee   An MCNPX2.7.0 study of Bragg peak degradation owing to density heterogeneity patterns for a CGMH therapeutic proton beam. Radiat. Physics Chem. 137:121-124. 2017 Aug. (SCI)
  6. S. M. Lin, H. Y Ku, T. C. Chang, T. W Liu and J. H. Hong*  The prognostic impact of overall treatment time on disease outcome in uterine cervical cancer patients treated primarily with concomitant chemoradiotherapy: a nationwide Taiwanese cohort study.  Oncotarget. doi: 10.18632/oncotarget.19617. 2017 July (SCI)
  7. W.R. Tang, J.H. Hong, K.M.Rau, C. H. Wang, Y. Y. Juang, C. H. Lai, M. Fujimori M, C.K. Fang Truth telling in Taiwanese cancer care: patients' and families' preferences and their experiences of doctors' practices. Psychooncology 26:999-1005, 2017 July (SCI)
  8. C. H. Li,  F. H. Chen, D. Schellingerhout, Y. S. Lin, J. H. Hong, H. L. Liu  Flow versus permeability weighting in estimating the forward volumetric transfer constant (Ktrans) obtained by DCE-MRI with contrast agents of differing molecular sizes. Magn Reson Imaging. 36: 105-111, 2017 Feb (SCI)
  9. F. Y. Liu, C. H. Lai, L. Y. Yang, C. C. Wang, G. Lin, C. J. Chang, W. Y.  Chang, S. H. Huang, Y. E. Huang, N. J. Peng, J. H. Hong, A. Chao, H. H. Chou, Y. C. Chang, T. C. Yen Utility of (18)F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy: a parallel study of a prospective randomized trial.  Eur J Nucl Med Mol Imaging. 43:1812-23. 2016 Sep. (SCI)
  10. F. H. Chen, C. C. Wang, H. L. Liu, S. Y. Fu, C. F. Yu, C. Chang, C. S. Chiang and J. H. Hong*   Decline of Tumor Vascular Function as Assessed by DCE-MRI is Associated with Poor Responses to Radiotherapy and Chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 95:1495-503, 2016 Aug. (SCI)
  11. H. C. Park, J.I. Yu, J. C. Cheng, Z. C. Zeng, J. H. Hong, M. L. Wang, M. S. Kim, K. H. Chi, P. C. Liang, R. C. Lee, W Y. Lau, K. H. Han, P. K. Chow, J. Seong  Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials. Liver Cancer. 5:162-74. 2016 July (SCI)
  12. K.C. Ho, Y. H. Fang, H. W. Chung, T. C.Yen, T. Y. Ho, H. H. Chou, J. H. Hong, Y. T. Huang, C. C. Wang, C. H. Lai.  A preliminary investigation into textural features of intratumoral metabolic heterogeneity in (18)F-FDG PET for overall survival prognosis in patients with bulky cervical cancer treated with definitive concurrent chemoradiotherapy.  Am J Nucl Med Mol Imaging. 6:166-75, 2016 July
  13. B. S. Huang, W. Y. Chen, C. W. Wang, A. L. Cheng, J. H. Hong* and S. H. Kuo* Relapse Pattern and Treatment Outcome of Curative Radiotherapy for Primary Cutaneous CD30+ Anaplastic Large-cell Lymphoma: A Retrospective Cohort Study. Acta Derm. Venereol. 96: 394–395, 2016 March (SCI)
  14. W. K. Kao, Y. L. Shen and J. H. Hong*  What are the Potential Benefits of Using Proton Therapy in Taiwanese Cancer Patients? 2015; Biomed J.  Sep-Oct; 38: 391-8.
  15. P.S. Jiang, C.F. Yu, C. Y. Yen, C. W. Woo, S. H. Lo, Y. K. Huang, J. H. Hong, C. S. Chiang Irradiation enhances the ability of monocytes as nanoparticle carrier for cancer therapy. PLoS One. 29;10:e0139043, 2015 Sep (SCI)
  16. C. C. Wang, H. H. Chou, L. Y. Yang, H. Lin, W. S. Liou, C. W. Tseng, F. Y. Liu, J. D. Liou, K. G. Huang, H. J. Huang, E. Y. Huang, C. H. Chen, T. C. Chang, C. J. Chang, J. H. Hong*, and C. H. Lai*  A randomized trial comparing concurrent chemoradiotherapy with single-agent cisplatin versus cisplatin plus gemcitabine in patients with advanced cervical cancer: An Asian Gynecologic Oncology Group study.  Gynecol. Oncol. 137: 462-7, 2015 June  (SCI)
  17. S. Y. Lin, C. S. Tsai, Y. C. Chang, K. K. Ng, T. C. Chang, W. H. Kao and J. H. Hong* The role of pretreatment FDG-PET in managing cervical cancer patients with enlarged pelvic lymph node(s) shown on MRI: a phase III randomized trial with long-term follow-up. Int. J. Radiat. Oncol. Biol. Phys. 92:977-985, 2015 July  (SCI)
  18. C. F. Yu, C. M. Lin, S.C. Wang, F. C. Chen, J. H. Hong, C. S. Tsai, Y. C. Yang and C. S. Chiang  Effects of pre-irradiation and SDF-1 suppression on the progression of murine astrocytoma cells grown in different stromal beds.   Int. J. Radiat. Biol. 90:1162-1168, 2014, Dec. (SCI)
  19. B.S. Huang, N.M. Tsang, S.M. Lin, D. Y. Lin, J. M. Lien, C. C. Lin, W. T. Chen, W.Y. Chen, J. H. Hong*  High-dose hypofractionated X-ray radiotherapy for hepatocellular carcinoma: Tumor responses and toxicities. Oncol. Lett. 6:1514-1520, 2013 Nov. (SCI)
  20. F.H. Chen, S.Y. Fu, Y.C. Yang, C.C. Wang, C.S. Chiang and J. H. Hong*  Combination of vessel-targeting agents and fractionated radiation therapy: the role of the SDF-1/CXCR4 pathway. Int. J. Radiat. Oncol. Biol. Phys., 86: 777-784, 2013 Jul. (SCI)
  21. C. F. Yu, J. H. Hong, C. S. Chiang The roles of macrophages and nitric oxide in interleukin-3-enhanced HSV-Sr39tk-mediated prodrug therapy PLoS One, 8: e56508 2013 Feb (SCI)
  22. J. J. Chen, S. Y. Fu, C.S. Chiang, J. H. Hong, C. K. Yeh A preclinical study to explore vasculature differences between primary and recurrent tumors using ultrasound Doppler imaging. Ultrasound Med. Biol. 39: 860-9, 2013 May (SCI)
  23. C. E. Wu, Y. C. Lin, J. H. Hong, C.K. Chuang, S. T. Pang, C.C. Liaw  Prognostic Value of Complete Response in Patients with Muscle-invasive Bladder Cancer Undergoing Concurrent Chemoradiotherapy Anticancer Res. 33: 2605-10, 2013 June (SCI)
  24. D. L. Tsan, K. H. Fan, Y.C. Chen, C. K. Chuang, C. C. Lee and J.H. Hong* Pre-radiotherapy PSA level as a predictor for biochemical control in prostate cancer patients receiving radiotherapy after radical prostatectomy. Biomed J.,  36:71-6, 2013 Mar-April
  25. Y. C. Lin, J. J. Wang, J. H. Hong, Y. P. Lin, C. C. Lee, Y. Y. Wai, S. H. Ng, Y. M. Wu, C. C. Wang  Noninvasive monitoring of microvascular changes with partial irradiation using dynamic contrast-enhanced and blood oxygen level-dependent magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys., 85:1367-74, 2013 April (SCI)
  26. P.F. Tsai, S. M. Lin, S. H. Lee, C. Y. Yeh, Y. T. Huang, C. C. Lee, J. H. Hong* The feasibility study of using multiple partial volumetric-modulated arcs therapy in early stage left-sided breast cancer patients. J Appl Clin Med Phys. 13:3806.  doi: 10.1120/jacmp.v13i5.3806, 2012 Sep.  (SCI)
  27. J. J. Chen, S. Y. Fu, C. S. Chiang, J. H. Hong and C. K. Yeh Characterization of tumor vasculature distribution in centeral and peripheral regions based on doppler ultrasound.  Med. Phys, 39,7490-7498, 2012  Dec. (SCI)
  28. C. C. Wang, C. H. Lai, Y. T. Huang, A. C. Chao, H. H. Chou and J. H. Hong*  HPV genotypes predict survival benefits from concurrent chemotherapy and radiation therapy in advanced squamous cell carcinoma of the cervix.  Int. J. Radiat. Oncol. Biol. Phys., 84:e499-506, 2012 Nov. (SCI)
  29. C. T. Wu, C. C. Hsieh, C. C. Lin, W. C. Chen, J. H. Hong and M. F. Chen  Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells.  J Mol Med (Berl). 90:1343-55, 2012 Nov (SCI)
  30. C. S. Chiang, S. Y. Fu, S. C. Wang, C. F. Yu, F. H. Chen, C. M. Lin, J. H. Hong Irradiation promotes an m2 macrophage phenotype in tumor hypoxia. Front. Oncol. 2:Article 89, 2012 Aug
  31. Y. T. Huang, C. C. Wang, C. S. Tsai, C. H. Lai, T. C. Chang, H. H. Chou,. P. Lee and J. H. Hong*  Clinical behaviors and outcomes for adenocarcinomas or adenosquamous carcinomas of cervix treated by radical surgery and adjuvant radiotherapy or chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 84: 420-427, 2012 Oct. (SCI)
  32. P. C. Pai, C.C. Chuang, C. K. Tseng, N. M. Tsang, K. P. Chang, T. C. Yen, C. T. Laio, J. H. Hong, J. T. Chang  Impact of pretreatment body mass index on patients with head-and-neck cancer treated with radiation. Int. J. Radiat. Oncol. Biol. Phys., 2012 May, 83: e93-e100  (SCI)
  33. K. J. Lin, C. C.Wu, Y. H. Pan, F.H. Chen, S.Y. Fu, C.S. Chiang, J.H. Hong, J.M. Lo  In vivo imaging of radiation-induced tissue apoptosis by (99m)Tc(I)-his (6)-annexin A5. Ann. Nucl. Med., 26: 272-80, 2012 April (SCI)
  34. K. H. Fan, Y. C. Chen,  W. M. Leung, C. K. Chuang, S. T. Pang and  J. H. Hong*, Adjuvant and Salvage Radiotherapy for Urothelial Cell Carcinoma of Upper Urinary Tract: A Single Institute Experience. Chang Gung Med. J. 35: 247-254, 2012 May-June,
  35. S. C. Wang, J. H. Hong, C. Hsueh, and C. S. Chiang Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model. Lab Invest. 92: 151-162, 2012 Jan (SCI)